# NHS Framework Agreement for the supply of Ranibizumab for the NHS in England

> Tender notice from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Tender value: £120,000,000
- Published: 9 January 2023
- Planned start: 1 April 2023
- Planned end: 31 March 2024
- Stage: open_tender
- Procurement category: goods
- Notice ID: ea3c29a8-6d1b-4321-9189-c7a5cbe92b5c-604025
- OCID: ocds-b5fd17-efe6e130-2169-44a2-a1b1-82665a895ff5

## Description

The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England\. Anti Veg-F medicines are currently used in the treatment of: a\. neovascular \(wet\) age-related macular degeneration \(AMD\); b\. visual impairment due to diabetic macular oedema \(DME/DMO\); c\. visual impairment due to myopic choroidal neovascularisation \(myopic CNV\); and d\. visual impairment due to macular oedema secondary to retinal vein occlusion \(branch RVO or central RVO\)\. Period of framework: 1 April 2023 to 31 March 2024 with an option to extend \(at the Authority's discretion\) for a further period \(or periods\) up to a total of 12 months \(i\.e\. total possible framework duration of 24 months\) Framework Reference Number: CMD/SCM/MJP/2023/01 Atamis Reference Number: C123966 http://health\.atamis\.co\.uk/

## Related contract awards

- [Identity Access Management - Service Adoption and Enablement](/contracts/ocds-b5fd17-08ebad6c-84fb-4e62-9afd-d06d220dd3a5): NHS England
- [OutSystems licenses for MAPPTI \(AP&P\)](/contracts/ocds-b5fd17-521fbf90-6e93-4366-b3bc-47aa2efd447d): NHS England
- [Provision of national e-portfolio 26/27](/contracts/ocds-b5fd17-7e027849-39ea-4eb8-8eb0-3b38f18dcca4): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/ea3c29a8-6d1b-4321-9189-c7a5cbe92b5c-604025)